Review Article

Amiodarone and thyroid hormone metabolism

W.M. Wiersinga¹ and M.D. Trip²

Departments of ¹Endocrinology and ²Cardiology, Academisch Medisch Centrum, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

Introduction

Amiodarone, an antiarrhythmic and anti-anginal agent, contains 75 mg of organic iodine per 200 mg active substance. The drug is deiodinated during its biotransformation, and it is estimated that a dose of 200 mg releases 6 mg of free iodine (Broekhuyzen et al., 1969). Consequently, the thyroid gland has to adjust itself to these pharmacological quantities of iodine. When amiodarone medication is discontinued, it may take months until the iodine excess is cleared from the body due to the very long elimination half-life (approximately 40–60 days) (Haffajee et al., 1983; Plomp et al., 1984). We will review the pharmacological and pathological effects of amiodarone on thyroid hormone metabolism, and discuss the relationship between the thyroidal effects of amiodarone and its mechanism of action.

Pharmacological effects of amiodarone on thyroid hormone metabolism

Short-term amiodarone medication, up to 4 weeks, results in increased plasma thyroxine (T₄), free thyroxine (FT₄) and reverse triiodothyronine (rT₃) concentrations and a decrease in plasma triiodothyronine (T₃) and free triiodothyronine (FT₃); these changes are accompanied with an increase of basal plasma thyrotropin (TSH) and peak TSH levels after TSH-releasing hormone (TRH), mostly within the normal range (Burger et al., 1976; Melmed et al., 1981). Continuation of amiodarone medication is associated with a further rise in plasma T₃, FT₃ and rT₃ and fall in plasma T₄; TSH levels return gradually to pre-treatment values. A steady-state in hormone plasma concentrations is reached after 12–16 weeks (Melmed et al., 1981). Amiodarone has no effect on plasma thyroxine-binding-globulin, nor does it interfere with the radioimmunoassays of thyroid hormones. Short-term amiodarone treatment is associated with a decrease of T₃ and T₄ production rate (PR) and of T₄ metabolic clearance rate (MCR); since the decrease in T₄-MCR is relatively greater than the decrease in T₃-PR, plasma T₄ values increase (Lambert et al., 1982). Long-term amiodarone treatment results in an increased T₄-PR and a decreased T₄-MCR (Lambert et al., 1982). No data are available on rT₃ kinetics in humans, but in rabbits rT₃-MCR is decreased by amiodarone (Kannan et al., 1984).

The initial decrease of T₄-PR can be explained by a transient inhibition of thyroid hormone secretion by the iodine excess derived from amiodarone (Vagenakis et al., 1973). The reduction in MCR of rT₃ and T₄ and the decrease in PR of T₃ appears to be caused by inhibition of type 5-deiodinase, the enzyme that catalyses T₄→T₃ and rT₃→3',3'-T₂ deiodination in liver. The generation of T₃ out of added T₄ is markedly reduced in a dose-related manner in liver homogenates from rats pretreated in vivo with amiodarone (Balsam & Ingbar, 1978; Sogol et al., 1983). If amiodarone is added in vitro the T₃ production from T₄ is inhibited when isolated rat hepatocytes are used (Aanderud et al., 1984), but not when liver homogenates are used (Sogol et al., 1983). This suggests that the effect of amiodarone is mediated via the plasma membrane. Indeed, amiodarone inhibits thyroid hormone uptake by rat hepatocytes in primary culture (Krenning et al., 1982). One might therefore hypothesize that amiodarone primarily inhibits tissue uptake of thyroid hormones, notably in the liver. This would explain the decrease in rT₃-MCR (the liver is an important site of rT₃ degradation — Silva et al., 1982), in T₄-MCR (sequential deiodination of T₄ is the major pathway of T₄ degradation — Engler & Burger, 1984), and in T₃-PR (by decreased availability of the substrate T₄ — the liver is a major production site of T₃).
Pathological effects of amiodarone on thyroid hormone metabolism

*Diagnosis of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH)*

Whereas the clinical and laboratory diagnosis of AIH poses no special problems, the diagnosis of AIT can be very difficult. Firstly, the anti-adrenergic effects of amiodarone might moderate the clinical signs and symptoms of thyrotoxicosis. Secondly, the diagnostic accuracy of thyroid hormone assays in plasma is decreased, as is obvious from Figure 1. Patients with an exaggerated TSH response to TRH had either a decreased plasma T₄ (group III B, in all cases associated with overt myxoedema) or no decreased plasma T₄ (group III A, associated with a clinically euthyroid state; these patients represent cases of subclinical hypothyroidism) (Evered *et al.*, 1973). The normal TRH-responders (group I) were all clinically euthyroid, despite grossly elevated T₄, FT₄ index and FT₄ values. Patients with a subnormal TSH response to TRH (group II) were judged to have overt thyrotoxicosis (group II B) or subclinical hyperthyroidism (group II A) by the presence or absence of signs and symptoms of thyrotoxicosis.

It is obvious that none of the thyroid function tests completely discrimates between the groups II B and II A. Thus, laboratory diagnosis of thyroid function

![Figure 1](http://pmj.bmj.com/) Individual and median values of plasma thyroid hormone concentrations of 59 patients on long-term amiodarone therapy, divided according to their TSH-response to 200 μg TRH i.v. (group I = normal, group II = decreased, and group III = increased response) and their clinical state (group A = euthyroid, group B = dysthyroid). Hatched areas indicate reference range of normal values, as obtained by RIA in 63 healthy volunteers in case of T₄, T₃U, FT₄ index, T₃, rT₃, and TSH response to TRH (Wiersinga & Toub, 1980) or as indicated by manufacturer in case of FT₄ (Corning Immo Phase FT₄ kit) and FT₃ (Amerlex-M Free T₃ RIA kit).
remains inconclusive in some patients, and clinical judgment must tell if they do or do not need antithyroid treatment. The introduction of the ultrasensitive immunoradiometric assay of TSH (TSH-IRMA) might greatly facilitate the laboratory diagnosis of thyroid function, since undetectable TSH-IRMA values are observed only in (subclinical) hyperthyroidism and reliably predict an absent TSH response to TRH (Seth et al., 1984). Consequently, if there is a detectable TSH-IRMA concentration in plasma in amiodarone-treated patients not exceeding the upper normal limit, no further action is needed; in the case of undetectable TSH-IRMA values, overt thyrotoxicosis is indicated by increased T3 or FT3 values but not excluded by normal T3 or FT3 values (Wiersinga et al., 1986).

**Incidence of AIT and AIH**

In a prospective Belgian study (Chevigne-Brancart et al., 1983) the incidence of AIT was 15.3% and AIH 8.5%. Interestingly, 80% of the hypothyroid cases occurred in the first year of amiodarone treatment in contrast with 30% of the hyperthyroid cases; after discontinuation of amiodarone treatment no new cases of hypothyroidism but five new cases of hyperthyroidism (17%) were observed within 6 months. An absent TSH response to TRH was encountered in 32% of patients who remained clinically euthyroid.

Another intriguing study related the incidence of amiodarone-induced dysthyroidism to dietary iodine intake (Martino et al., 1984b): in iodine-deplete areas, AIT is more prevalent than AIH, whereas in iodine-replete areas there exists a preponderance of hypothyroid over hyperthyroid cases.

**Pathogenesis of AIT and AIH**

The pathogenesis of iodine-induced dysthyroidism is essentially unknown. The degree of iodine excess is similar in euthyroid, hyperthyroid and hypothyroid patients on long-term amiodarone therapy (Trip et al., 1983; Eason et al., 1984) and is therefore not the determinant *per se*.

Some pre-existent thyroid abnormality may be unmasked by iodine excess, and the likelihood of such a mechanism in AIH is substantiated by its development relatively early in the course of treatment and by its preponderance in females (autoimmune thyroiditis is more common in women than in man). The precipitation of overt hyperthyroidism by iodine excess in patients with previous thyroid abnormalities is also well known (Fradkin & Wolff, 1983), but it cannot be denied that iodide-induced hyperthyroidism also occurs in patients in whom, after recovery, thyroid function and regulation appears to be perfectly normal (Savoie et al., 1975). The steady appearance of new hyperthyroid cases with continuation of

---

**Figure 2** A hypothetical scheme on the mechanism of action of amiodarone by the induction of a local ‘hypothyroid-like’ condition in the heart. The duration of cardiac action potentials is viewed as a postreceptor effect of nuclear T₃-receptors in the heart. Receptor occupancy is decreased in hypothyroid and in amiodarone-treated patients, resulting in an identical lengthening of the action potential (modified according to Nademanee et al., 1983).
amiodarone therapy (Chevigné-Brancart et al., 1983) also indicates a different pathogenesis in this group of patients, which remains unexplained. Lastly, iodine may facilitate the development of autoimmune thyroid disease (McGregor et al., 1985): 55% of patients taking amiodarone for 30 days developed thyroid microsomal antibodies (Monteiro et al., 1986).

Treatment of AIT and AIH

Discontinuation of amiodarone medication is the most logical approach in the treatment of AIT and AIH, but is not always feasible because of the presence of cardiac disease requiring amiodarone treatment. The management of AIH is relatively easy: withdrawal of amiodarone, and/or T₄ substitution. Management of AIT is more difficult, mainly because of a lower effectiveness of antithyroid drugs and radioactive iodine during iodine excess. Thyroidectomy is a rigorous treatment for a self-limiting disease and may carry a high operative risk in these cardiac patients. Spontaneous cure in non-treated cases is observed within an average of 6 months; a phase of slight hypothyroidism precedes the return to euthyroidism (Léger et al., 1984).

High doses of prednisone, up to 60 mg/day, are reported to have a dramatic effect, with a return of plasma T₃ and T₄ to normal values in 2 weeks (Staëübi et al., 1981; Wimpfheimer et al., 1982; Léger et al., 1984). Recently, a combination of methimazole (40 mg/day) and potassium perchlorate (1 g/day until euthyroidism is reached) has been advocated (Martino et al., 1984a). Inhibition of iodine uptake by perchlorate results in a greater effectiveness of methimazole, and 8 out of 9 patients thus treated were euthyroid within 45 days. Potassium perchlorate may also be useful in AIH: euthyroidism was reached in 3 months by discontinuation of amiodarone, but in 15–20 days if potassium perchlorate was given (Martino et al., 1985).

Relation of thyroid hormone effects of amiodarone to its mechanism of action

The pharmacological actions of amiodarone include bradycardia, depression of myocardial oxygen consumption and lengthening of the cardiac action potent-}

References


ANASTASIOU-NANA, M., KOUTRAS, D.A., LEVIS, G., SOUV.


KRENNING, E.P., DOCTER, R., BERNARD, H.F., VISSER, T.J. & HENNEMANN, G. (1982). Decreased transport of thyroxine (T₄), 3,3′, 5-triiodothyronine (T₃) and 3,3′,5′-triiodothyronine (rT₃) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. *FEBS Letters*, 140, 229.


Amiodarone and thyroid hormone metabolism.

W. M. Wiersinga and M. D. Trip

Postgrad Med J 1986 62: 909-914
doi: 10.1136/pgmj.62.732.909

Updated information and services can be found at:
http://pmj.bmj.com/content/62/732/909.citation

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/